Genetic Technologies PE Ratio 2006-2021 | GENE

Current and historical p/e ratio for Genetic Technologies (GENE) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Genetic Technologies PE ratio as of October 22, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Genetic Technologies PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-22 2.85 inf
2021-06-30 4.25 0 0.00
2020-12-31 3.60 0 0.00
2020-06-30 2.28 0 0.00
2019-12-31 1.99 0 0.00
2019-06-30 2.36 0 0.00
2018-12-31 2.19 0 0.00
2018-06-30 3.96 0 0.00
2017-12-31 4.64 0 0.00
2017-06-30 3.60 0 0.00
2016-12-31 4.32 0 0.00
2016-06-30 8.36 0 0.00
2015-12-31 10.72 0 0.00
2015-06-30 12.16 0 0.00
2014-12-31 7.70 0 0.00
2014-06-30 21.20 0 0.00
2013-12-31 28.60 0 0.00
2013-06-30 46.50 0 0.00
2012-12-31 43.60 0 0.00
2012-06-30 73.00 0 0.00
2011-12-31 60.60 0 0.00
2011-06-30 138.40 0 0.00
2010-12-31 21.10 0 0.00
2010-06-30 19.20 0 0.00
2009-12-31 23.00 0 0.00
2009-06-30 27.40 0 0.00
2008-12-31 21.00 0 0.00
2008-06-30 49.00 0 0.00
2007-12-31 80.20 0 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.044B $0.000B
Genetic Technologies was the first company in the world to recognize important new applications for `non-coding` DNA (DeoxyriboNucleic Acid). The Company has since been granted patents securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76